Tiny study tests how liver disease changes drug processing

NCT ID NCT07049939

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug bomedemstat behaves in people with mild or moderate liver impairment compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal is to understand if liver problems require dose adjustments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bomedemstat (MK-3543)
What this could lead to: If successful, this study could help doctors decide the right dose of bomedemstat for people with liver problems.
What could go wrong: This is a very early, small study with only 9 participants, so results may not apply to everyone. The drug may still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY

Contacts and locations

Locations

Orlando Clinical Research Center ( Site 0001)

Orlando, Florida, 32809, United States
The Texas Liver Institute ( Site 0002)

San Antonio, Texas, 78215, United States
University of Miami ( Site 0003)

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.